Active Biotech AB Interim Report January – September 2010

Oct 27, 2010 08:30 (CEST) 
* Laquinimod ― Phase III trials proceeding as planned, results from Phase II
    extension study published in scientific journal
  * TASQ ― preparations ongoing for start of Phase III in first half of 2011
  * ANYARA ― ongoing phase III trial expected to be concluded in first half of
    2012
  * 57-57 ― exploratory SLE clinical trial completed
  * ISI ― project continuing according to plan
  * RhuDex(TM) ― preparations for continued clinical development in progress
  * Net sales of SEK 8.5 M (7.7)
  * Operating loss of SEK 149.7 M (loss: 164.6)
  * Loss after tax SEK 156.8 M (loss: 165.1)
  * Loss per share for the period amounted to SEK 2.40 (loss: 2.90)


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans
Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00


This report is also available at www.activebiotech.com




[HUG#1455517]





Active Biotech AB Interim Report January-September 2010:
http://hugin.info/1002/R/1455517/395393pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE